Dermata Therapeutics (DRMA) Competitors $6.02 +0.22 (+3.70%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. SYBX, LEXX, LPCN, BLRX, GELS, TRIB, EDSA, ALLR, MTEX, and ATHAShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Synlogic (SYBX), Lexaria Bioscience (LEXX), Lipocine (LPCN), BioLineRx (BLRX), Gelteq (GELS), Trinity Biotech (TRIB), Edesa Biotech (EDSA), Allarity Therapeutics (ALLR), Mannatech (MTEX), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors Synlogic Lexaria Bioscience Lipocine BioLineRx Gelteq Trinity Biotech Edesa Biotech Allarity Therapeutics Mannatech Athira Pharma Synlogic (NASDAQ:SYBX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Which has preferable valuation and earnings, SYBX or DRMA? Dermata Therapeutics has lower revenue, but higher earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$10K1,731.60-$23.36M-$2.51-0.59Dermata TherapeuticsN/AN/A-$12.29M-$16.41-0.36 Does the media prefer SYBX or DRMA? In the previous week, Dermata Therapeutics had 4 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for Dermata Therapeutics and 2 mentions for Synlogic. Dermata Therapeutics' average media sentiment score of 0.85 beat Synlogic's score of 0.43 indicating that Dermata Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Synlogic Neutral Dermata Therapeutics Positive Which has more volatility and risk, SYBX or DRMA? Synlogic has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Do analysts prefer SYBX or DRMA? Dermata Therapeutics has a consensus price target of $30.00, indicating a potential upside of 401.67%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of SYBX or DRMA? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 3.0% of Synlogic shares are held by company insiders. Comparatively, 18.5% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is SYBX or DRMA more profitable? Synlogic's return on equity of -8.09% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -8.09% -5.50% Dermata Therapeutics N/A -214.98%-153.76% SummaryDermata Therapeutics beats Synlogic on 9 of the 14 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.96M$3.11B$5.67B$9.83BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-0.3620.3830.5825.12Price / SalesN/A367.51464.55116.64Price / CashN/A42.3037.4059.05Price / Book0.738.659.096.18Net Income-$12.29M-$54.65M$3.25B$264.89M7 Day Performance-4.93%6.59%4.76%2.66%1 Month Performance-18.12%9.57%6.72%3.05%1 Year Performance-70.97%14.06%30.51%25.05% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics3.2677 of 5 stars$5.98+2.9%$30.00+401.7%-74.3%$3.96MN/A-0.368Negative NewsEarnings ReportShort Interest ↓Gap UpSYBXSynlogic0.9689 of 5 stars$1.45-3.1%N/A+2.8%$17.01M$10K-0.5880Short Interest ↑Gap UpHigh Trading VolumeLEXXLexaria Bioscience3.7971 of 5 stars$0.87-0.7%$4.00+360.3%-75.1%$17.00M$460K-1.307News CoverageShort Interest ↓LPCNLipocine2.886 of 5 stars$3.17+1.3%$9.00+183.9%-19.6%$16.96M$11.20M-3.1110News CoverageBLRXBioLineRx3.3216 of 5 stars$3.95+2.7%$26.00+559.1%-87.8%$16.82M$22.34M-0.4540News CoverageEarnings ReportUpcoming EarningsGELSGelteqN/A$1.69+1.2%N/AN/A$15.95M$100K0.00N/ATRIBTrinity Biotech1.488 of 5 stars$0.87+6.4%N/A-27.4%$15.71M$61.56M-0.30480News CoverageGap DownEDSAEdesa Biotech2.0905 of 5 stars$2.23-2.0%$5.00+124.7%-49.7%$15.64MN/A-1.4020Earnings ReportShort Interest ↓Gap UpALLRAllarity Therapeutics3.4026 of 5 stars$1.04+2.5%$9.00+769.6%-79.3%$15.61MN/A0.0010News CoverageEarnings ReportUpcoming EarningsMTEXMannatech0.4466 of 5 stars$8.00-5.3%N/A+40.2%$15.19M$117.87M-79.95250News CoverageEarnings ReportShort Interest ↑Gap DownATHAAthira Pharma3.7085 of 5 stars$0.38+1.8%$11.25+2,876.2%-86.2%$14.76MN/A-0.1840News Coverage Related Companies and Tools Related Companies SYBX Competitors LEXX Competitors LPCN Competitors BLRX Competitors GELS Competitors TRIB Competitors EDSA Competitors ALLR Competitors MTEX Competitors ATHA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access